Classifications

• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
  • C09B23/0075—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of an heterocyclic ring
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
  • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
  • C09B23/0033—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through a sulfur atom
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
  • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
  • C09B23/005—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being a COOH and/or a functional derivative thereof
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
  • C09B23/0066—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)

Definitions

• cells are labeled with a fluorochronie compound described herein and (he resulting labeled cells administered to the subject.
• the signal emitted by the fluorochrome compound can be used to monitor transport and localization of the cells or to evaluate the efficacy of a cell therapy.
• the invention provides an in vitro optical imaging method.
• the fluorochrome compounds of the invention can be represented by the formula Z'-PMB-Z 2 , and salts thereof, wherein Z 1 and Z 2 each independently represent the same or different polycyclic groups containing a heterocyclic moiety, and PMB represents a polymethine bridge comprising a bridged polycyclo moiety.
• Z 1 and Z 2 each independently represent the same or different polycyclic groups containing a heterocyclic moiety
• PMB represents a polymethine bridge comprising a bridged polycyclo moiety.
• alkyl and alkylaryl are art-recognized and refer to an alkyl group substituted with an aryl group (e.g.. an aromatic or heteroaromatic groupj.
• alkenyl and alkynyT are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively.
• heteroatom is art-recognized and refers to an atom of any element other than carbon or hydrogen.
• Illustrative heteroatoms include boron, nitrogen, oxygen. phosphorus, sulfur and selenium.
• aryl is art-recognized and refers to 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole. pyridine, pyrazine, pyridazine and pyrimidine, and the like.
• aryl groups having heteroatoms in the ring structure may also be referred to as "heteroaryP or "heteroaromatics.”
• the aromatic ring may be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, aikenyl, alkynyl, cycloalkyl, hydroxy 1, alkoxyl, amino, nitro, sulfhydryl, imino.
• the heterocyclic ring may be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl. alkynyl. cycloalkyl, hydroxy 1, amino, nitro, sulthydryl, imino. amido. phosphonate, phosphinatc. carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF-,, -CN, or the like.
• polycyclyl polycyclic group " ' or “polycyclo moiety'” are art- recognized and refer to two or more rings (e.g., cycloalkyls. cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings arc "fused rings. ' ' Rings that are joined through non-adjacent atoms arc termed "bridged * ' rings.
• Each of the rings of the polycycle may be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl. imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF ⁇ , -CN, or the like.
• amino is art recognized as an amino-substituted carbonyl and includes a moiety that may be represented by the general formula:
• alkoxyl' or "alkoxy'” are art-recognized and refer to an alkyl group, as defined above, having an oxygen attached thereto.
• Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-bntoxy and the like.
• An "'ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as may be represented by one of -O-alkyl, -O-alkenyl, -O-alkyny r l, -0-(CH ? ) m -R 61 , where m and R 61 are described above.
• the term ""sulfonate” is art recognized and refers to a moiety that may be represented by the general formula:
• sulfoxide is art-recognized and refers to a moiety that may be represented by the general formula:
• R b o represents a lower alkyl or an aryl.
• Analogous substitutions may be made to alkcnyl and alkynyl groups to produce, for example, aminoalkenyls, aminoalkynyls, amidoalkenyls, amidoalkynyls, iminoalkenyls, iminoalkynyls, tliioalkenyls. thioalkynyls. carbonyl-substituted alkenyls or alkynyls.
• each expression e.g., alkyl, m, n, and the like, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
• substitution " ' or “substituted with'” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
• substitution ' is also contemplated to include all permissible substituents of organic compounds.
• the permissible substituents include acyclic and cyclic, branched and unbranched. carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative s ⁇ bstituents include, for example, those described herein above.
• the permissible substituents may be one or more and the same or different for appropriate organic compounds.
• the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible subslituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
• polymethine bridge refers to a conjugated double bond methylene chain comprising an odd number of carbons. Such a bridge can include a ring structure as part of the conjugated double bond methylene chain.
• compositions are described as having, including, or comprising specific components, it is contemplated that compositions also consist essentially of. or consist of. the recited components.
• processes are described as having. including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps.
• order of steps or order for performing certain actions are immaterial so long as the invention remains operable.
• two or more steps or actions may be conducted simultaneously.
• Z 1 and Z 2 each independently represent a polycyclic group comprising a heterocyclic moiety.
• Z 1 and Z 2 each independently can be selected from a substituted or uns ⁇ bstituted indolinium or a benzindolinium ring.
• PMB represents a polymethine bridge comprising a bridged polycyclo moiety.
• the compounds have an absorption and emission wavelengths in the range from about 500 nm to about 1100 nm, preferably in the range from about 600 nm to about 900 nm.
• Such a reactive group can include, for example, an electrophile or nucleophile that can form a covalent linkage via exposure to a corresponding functional group that is a nucleophile or eiectrophile, respectively.
• the reactive group is a photoactivatable group, and becomes chemically reactive only after illumination with light of an appropriate wavelength.
• a reaction between the compound of the invention and the biomolecule to be linked can result in one or more atoms of a reactive group incorporated into a new linkage attaching a compound of the invention to the conjugated substance.
• Biomolecules contemplated herein include, but are not limited to, proteins (for example, enzymes, hormones, antibodies and antigen binding fragments thereof, and single chain antibodies), peptides, amino acids, glycoproteins, ligands for ceil receptors, polysaccharides, carbohydrates, nucleic acids (for example, DNA and RNA), nucleosides, nucleotides, aptamers, peptidyl nucleic acids, cell receptors, enzyme substrates, enzyme cofactors, biotin, hormones, neurotransmitters, growth factors, cytokines, lymphokines. lectins, selectins, lipids, lipid assemblies (for example, micelles or vesicles), and toxins.
• proteins for example, enzymes, hormones, antibodies and antigen binding fragments thereof, and single chain antibodies
• peptides amino acids
• glycoproteins for ceil receptors
• polysaccharides carbohydrates
• nucleic acids for example, DNA and RNA
• nucleosides for example,
• biomolecules can be used, such as those involved in targeting and delivery such as folate - mediated targeting (Leamon & Low, Drug Discovery Today, 6:44-51 , 2001), transferrin, vitamins, carbohydrates and ligands that target internalizing receptors, including, but not limited to, asialoglycoprotein receptor, somatostatin, nerve growth factor, oxytocin, bombesin, calcitonin, arginine vasopressin, angiotensin II, atrial natriuretic peptide, insulin, glucagons, prolactin, gonadotropin, various opioids and urokinase-type plasminogen activator.
• folate - mediated targeting Leamon & Low, Drug Discovery Today, 6:44-51 , 2001
• transferrin vitamins, carbohydrates and ligands that target internalizing receptors, including, but not limited to, asialoglycoprotein receptor, somatostatin, nerve growth factor, oxytocin, bombe
• Biomolecules can also include organic molecules, polymers, dendrimers, cells (for example, mammalian cells, non mammalian cells, plant cells, insect cells, embryonic cells). bacteria, bacteriophage, viruses, organisms, particles, microparticles, or nanoparticles. Biomolecules can also include therapeutic drug molecules including but not limited to phototherapy or radiotherapy molecules.
• the compounds of the present invention having a sufficiently basic group, such as an amine can react with an organic or inorganic acid to form an acid addition salt.
• Acids commonly employed to form acid addition salts from compounds with basic groups are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
• salts include the sulfate, pyrosulfate, bisulfate. sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate. caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne- 1 ,4-dioate, hexyne- 1. ⁇ -dioate.
• X4 and X5 each independently are selected from the group (CKiK 2 ),; NR', -NR 5 R 9 T 11 O, and S; i is an integer selected from 1 to 7;
• R « independently is selected from the group consisting of H, C 1 -C 2 O alkyl, aryl and alkylaryl; R 7 and Rs, when taken in combination, optionally form a 4-, 5-, 6- or 7-member, optionally substituted, saturated or unsaturated ring;
• X 3 can be selected from the group consisting of: 0-(CH 2 ),- T 1 , S-(CH 2 VT 1 , 0-Ph-(CH 2 ) J -Ti. S -Ph-(CH 2 ) r T 1 , wherein j is an integer from 0 to 6, and Ph is phenyl.
• Ti is selected from the group consisting of -NH 2 , -OH, -SH, -SO 3 H. carboxyl. -COCl, -(CO)O(CO)Ri 3 , -CONHNH 2 , substituted and unsubstituted N- hydroxysuccinimido esters, substituted and unsubstituted N-hydroxysulfosuccinimido esters, nitro- or fluoro-phenol esters, azide, -NCS. -CHO, azide, -COCH 2 I, phosphoraraidite, phthalamido, and maleimide, wherein Ri 3 is selected from the group consisting of H, alkyl and aryl.
• T 2 is O or S
• X 5 is N-Me or CHT
• R I 1 is selected from the group consisting of SO 3 H, COOH, OH, SH, and NH 2
• Ri 2 is selected from the group consisting of: H, SO 3 H, NCS, (CH2)kC00H, wherein k is an integer from O to 6.
• the invention provides compounds of general structural formulae 40 and 41 :
• Ri, R 2 , R3, R4, R5. RO, R9, Wi, W 2 , Xi, X 2 , X3. X4, X 5 , Ti, 1I 1 , and n 2 , are as defined herein, Y " is a counterfoil, and BM is a biomolecule.
• BM a biomolecule
• the foregoing structures are exemplary and it is understood that a biomolecule (BM) can be chemically linked to such compound via any one or more of the groups identified as Rj , R 2 , R3, R 4 , R 5 - R 6 , R9, Wi, W 2 , XJ , X 2 , X 3 . X 4 , Xs, and T 1 .
• compositions suitable for administration to a subject can be formulated in a pharmaceutical composition suitable for administration to a subject, for example, an animal or human subject.
• the formulations include the compounds together with a physiologically acceptable carrier suitable for the desired form and/or dose of administration.
• Physiologically acceptable carriers can include water, saline, and may further include agents such as buffers, and other agents such as preservatives that are compatible for use in pharmaceutical formulations.
• the preferred carrier is a fluid, preferably a liquid, more preferably an aqueous solution; however, carriers for solid formulations, topical formulations, inhaled formulations, ophthalmic formulations, and transdermal formulations are also contemplated as within the scope of the invention.
• the pharmaceutical compositions can include one or more stabilizers in a physiologically acceptable carrier.
• stabilizers for use in such compositions include, for example, low molecular weight carbohydrates, for example a linear polyalcohol, such as sorbitol, and glycerol.
• Other low molecular weight carbohydrates, such as inositol, may also be used.
• the composition may be in the form of, e.g., solid tablets, capsules, pills, powders including lyophilized powders, colloidal suspensions, microspheres, liposomes granulates, suspensions, emulsions, solutions, gels, including hydrogels, pastes, ointments, creams, plasters, irrigation solutions, drenches, osmotic delivery devices, suppositories, enemas, injectables, implants, sprays, or aerosols.
• the pharmaceutical compositions can be formulated according to conventional pharmaceutical practice (see, for example. Remington: The Science and Practice of Pharmacy. 20th edition, 2000. ed. A.R.
• An imaging system useful in the practice of this invention typically includes three basic components: (1) an appropriate light source for exciting the fluorochrome compounds of the invention, (2) a system for separating or distinguishing emissions from light used for inducing fluorochrome excitation, and (3) a detection system.
• This detection system can be hand-held or incorporated into other useful imaging devices such as endoscopes, catheters, intraoperative microscopes and/or viewers.
• Other types of light gathering components are catheter-based devices, including fiber optics devices. Such devices are particularly suitable for intravascular imaging. See, for example. Tearney et al, Science 276: 2037-2039, 1997; and Circulation 94: 3013, 1996.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Plural Heterocyclic Compounds (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Indole Compounds (AREA)
• Apparatus For Radiation Diagnosis (AREA)
• Magnetic Resonance Imaging Apparatus (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (2)

Family

ID=39690741

Family Applications (1)

Country Status (6)

Cited By (7)

Families Citing this family (14)

Family Cites Families (55)

• 2008
  • 2008-02-08 JP JP2009549253A patent/JP5643514B2/ja active Active
  • 2008-02-08 DK DK08729371.8T patent/DK2118206T3/en active
  • 2008-02-08 WO PCT/US2008/053399 patent/WO2008100817A2/en not_active Ceased
  • 2008-02-08 EP EP08729371.8A patent/EP2118206B9/en active Active
  • 2008-02-08 US US12/028,209 patent/US8221721B2/en not_active Expired - Fee Related
  • 2008-02-08 ES ES08729371.8T patent/ES2670852T3/es active Active
• 2012
  • 2012-07-13 US US13/548,451 patent/US9365721B2/en active Active
• 2014
  • 2014-03-31 JP JP2014071365A patent/JP2014167119A/ja not_active Withdrawn

Also Published As

Similar Documents

Legal Events